Cryoablation Combined With Tislelizumab Plus Lenvatinib in 1L Treatment of Advanced HCC (CASTLE-10)

Hepatocellular Carcinoma Clinical Trial

— CASTLE-10  

Official title:

A Phase II Study to Evaluate the Efficacy and Safety of Cryoablation Combined With Tislelizumab Plus Lenvatinib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05897268
• Other study ID #: 2305274-8
• Status: Recruiting
• Phase: Phase 2
• Start date: June 20, 2023
• Est. completion date: December 30, 2025

Study information

• Verified date: June 2023
• Source: Fudan University
• Contact: Peng Wang, MD
• Phone: 86-21-64175590
• Email: wangp413[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this study is to evaluate the efficacy and safety of cryoablation combined with Tislelizumab plus Lenvatinib as first-line treatment in patients with advanced HCC.

Description:

Recent studies have suggested that local destruction of tumor tissue by cryoablation induced activation and maturation of dendritic cells and tumor-specific T cells by cross-presentation of tumor antigens. While pd-1 blocking antibody interferes with PD-1 mediated T-cell regulatory signaling. And combination of pd-1 blocking antibody plus lenvatinib showed increased ORR in many types of human cancers. Therefore, the objective of this study is to evaluate the efficacy and safety of cryoablation combined with Tislelizumab plus lenvatinib as first-line treatment in patients with advanced HCC.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 25
• Est. completion date: December 30, 2025
• Est. primary completion date: December 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Written informed consent obtained.

• Age = 18 years at time of study entry.

• Hepatocellular carcinoma confirmed by histology/cytology.

• No systematic anti-tumor treatment has been performed.(End of postoperative adjuvant chemotherapy for more than 6 months allowed).

• Barcelona Clinic Liver Cancer stage C. BCLC stage B, not suitable for radical surgery and/or local treatment.

• At least one measurable site of disease as defined by RECIST v1.1 with spiral CT scan or MRI.

• Child-Pugh: <=7

• Performance status (PS) = 2 (ECOG scale).

• Life expectancy of at least 12 weeks.

• Adequate blood count, liver-enzymes, and renal function: absolute neutrophil count = 1,500/L, platelets =75 x103/L; Total bilirubin = 3x upper normal limit; Aspartate Aminotransferase (SGOT), Alanine aminotransferase (SGPT) = 5 x upper normal limit (ULN); International normalized ratio (INR) =1.25; Albumin = 31 g/dL; Serum Creatinine = 1.5 x institutional ULN or creatinine clearance (CrCl) = 30 mL/min (if using the Cockcroft-Gault formula )

• Female patients with reproductive potential must have a negative urine or serum pregnancy test within 7 days prior to start of trial.

• Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment, adherence to contraceptive measures, scheduled visits and examinations including follow up.

Exclusion Criteria:

• With fibrous lamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma,

1. cholangiocarcinoma components in tumor tissues.

• Have a history of hepatic encephalopathy or have a history of liver transplantation.

• With clinical symptoms requires drainage of pleural effusion, ascites or pericardial effusion.

• Central nervous system (CNS) metastasis.

• History of cardiac disease, including clinically significant gastrointestinal bleeding within 4 weeks prior to start of study treatment.

• Thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within the 6 months Prior to the first dose of study drug with the exception of thrombosis of a segmental portal vein.

• Major surgery within 4 weeks of starting the study treatment OR subjects who have not recovered from effects of major surgery.

• Patients with second primary cancer, except adequately treated basal skin cancer or carcinoma in-situ of the cervix.

• Immunocompromised patients, e.g. patients who are known to be serologically positive for human immunodeficiency virus (HIV).

• Any condition or comorbidity that, in the opinion of the investigator, would interfere with evaluation of study Treatment or interpretation of patient safety or study results, including but not limited to:

1. history of interstitial lung disease

2. Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) coinfection (i.e double infection)

3. known acute or chronic pancreatitis

4. active tuberculosis

5. any other active infection (viral, fungal or bacterial) requiring systemic therapy

6. history of allogeneic tissue/solid organ transplant

7. diagnosis of immunodeficiency or patient is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of Tislelizumab treatment.

Has an active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents. Exceptions: Subjects with vitiligo, hypothyroidism, diabetes mellitus type I or resolved childhood asthma/atopy are an exception to this rule. Subjects that require intermittent use of bronchodilators or local steroid injections would not be excluded from the study. Subjects with Hashimoto thyroiditis, hypothyroidism stable on hormone replacement or psoriasis not requiring treatment are not excluded from the study.

i) Live vaccine within 30 days prior to the first dose of Tislelizumab treatment or during study treatment.

j) History or clinical evidence of Central Nervous System (CNS) metastases Exceptions are: Subjects who have completed local therapy and who meet both of the following criteria: I. are asymptomatic and II. have no requirement for steroids 6 weeks prior to start of Tislelizumab treatment. Screening with CNS imaging (CT or MRI) is required only if clinically indicated or if the subject has a history of CNS

• Medication that is known to interfere with any of the agents applied in the trial.

• Any other efficacious cancer treatment except protocol specified treatment at study start.

• Female subjects who are pregnant, breast-feeding or male/female patients of reproductive potential who are not employing an effective method of birth control (failure rate of less than 1% per year). [Acceptable methods of contraception are: implants, injectable contraceptives, combined oral contraceptives, intrauterine pessars (only hormonal devices), sexual abstinence or vasectomy of the partner]. Women of childbearing potential must have a negative pregnancy test (serum ß-HCG) at screening.

• Patient with any significant history of non-compliance to medical regimens or with inability to grant reliable informed consent.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular
• Hepatocellular Carcinoma

Intervention

Procedure:
• Cryoablation
Cryoablation is performed under US or CT guidance per Investigator decision.

Drug:
• Tislelizumab
a PD-1 immune check inhibitor
• Lenvatinib
Lenvatinib capsules

Locations

Country	Name	City	State
China	Fudan University Shanghai Cancer Center	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Fudan University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective Response Rate (ORR) evaluated by the investigator per Response Evaluation Criteria in Solid Tumors Version 1.1	ORR is defined as the percentage of participants who have a confirmed complete response (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters). Responses are according to RECIST 1.1 as assessed by investigator.	max 24 months
Secondary	Progression Free Survival (PFS) evaluated by the investigator per Response Evaluation Criteria in Solid Tumors Version 1.1	PFS is defined as the time from study treatment to disease progression or all-cause death as assessed by the investigator (whichever occurs first)	max 24 months
Secondary	Overall survival (OS) evaluated by the investigator per Response Evaluation Criteria in Solid Tumors Version 1.1	OS is defined as the time from study treatment to the date of death of the subject, regardless of the cause of death	max 24 months
Secondary	Duration of Response (DOR) evaluated by the investigator per Response Evaluation Criteria in Solid Tumors Version 1.1	DOR is defined as the time from first documented complete or partial response until disease progression, death from any cause, or censoring at date of last tumor assessment.	max 24 months
Secondary	Disease control rate (DCR) evaluated by the investigator per Response Evaluation Criteria in Solid Tumors Version 1.1	DCR is defined as the proportion of patients with complete response (CR), partial response (PR) and stable disease (SD)	max 24 months
Secondary	Objective Response Rate (ORR) evaluated by the investigator per HCC-specific modified Response Evaluation Criteria in Solid Tumors (mRECIST)	ORR is defined as the percentage of participants who have a confirmed complete response (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters). Responses are according to mRECIST as assessed by investigator.	max 24 months
Secondary	Progression Free Survival (PFS) evaluated by the investigator per mRECIST	PFS is defined as the time from study treatment to disease progression or all-cause death as assessed by the investigator (whichever occurs first)	max 24 months
Secondary	Overall survival (OS) evaluated by the investigator per mRECIST	OS is defined as the time from study treatment to the date of death of the subject, regardless of the cause of death	max 42 months
Secondary	Duration of Response (DOR) evaluated by the investigator per mRECIST	DOR is defined as the time from first documented complete or partial response until disease progression, death from any cause, or censoring at date of last tumor assessment.	max 24 months
Secondary	Disease control rate (DCR) evaluated by the investigator per mRECIST	DCR is defined as the proportion of patients with complete response (CR), partial response (PR) and stable disease (SD)	max 24 months
Secondary	Number of participants with treatment-related adverse events as assessed by CTCAE v5.0	An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experience at least one AE will be reported.	max 42 months